Cochrane · systematic review · CD009068
Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked dilated cardiomyopathy
Bourke, JP, Bueser, T, Quinlivan, R · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
15
No studies
9
Included studies
NR
No studies 9 · 37.5%Ungraded 0 · 0%Very low 12 · 50%Low 3 · 12.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Prophylactic perindopril (2 mg to 4 mg daily) versus placebo in DMD
Population: boys with DMD, normal cardiac examination and LVEF > 55% at baseline
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cardiac function: number of patients with EF < 45% Prophylactic perindopril (2 mg to 4 mg daily) vs placebo | RR 1.04 [0.07, 15.77] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Size of metabolically abnormal areas of myocardium Prophylactic perindopril (2 mg to 4 mg daily) vs placebo | no estimate extracted | NR | No studies |
Improvements in quality of life measures Prophylactic perindopril (2 mg to 4 mg daily) vs placebo | no estimate extracted | NR | No studies |
Adverse events Prophylactic perindopril (2 mg to 4 mg daily) vs placebo | RR 1.16 [0.78, 1.72] | 1 study · 57 participants | Low Downgraded: risk of bias, imprecision |
Lisinopril (0.7 mg/kg daily) versus losartan (0.7 mg/kg daily) for established cardiomyopathy in DMD
Population: patients with established cardiomyopathy in DMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiac function: Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily) | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Size of metabolically abnormal areas of myocardium Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily) | no estimate extracted | NR | No studies |
Improvements in quality of life measures Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily) | no estimate extracted | NR | No studies |
Adverse events Lisinopril (0.7 mg/kg daily) vs losartan (0.7 mg/kg daily) | no estimate extracted | 1 study · 22 participants | Very low Downgraded: risk of bias, imprecision |
Idebenone (3 daily tablets of 150 mg) versus placebo for subclinical cardiomyopathy in DMD
Population: boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cardiac function (change in fractional shortening) Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: imprecision, indirectness |
Change in cardiac function (change in ejection fraction) Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | 1 study · 21 participants | Very low Downgraded: imprecision, indirectness |
Change in cardiac function (change in peak systolic radial strain in LV lateral wall segments) Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | 1 study · 18 participants | Very low Downgraded: imprecision, indirectness |
Change in cardiac function (change in systolic radial strain rate LV inferolateral wall) Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | 1 study · 18 participants | Very low Downgraded: imprecision, indirectness |
Size of metabolically abnormal areas of myocardium Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | NR | No studies |
Improvements in quality of life measures Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | NR | No studies |
Adverse events Idebenone (3 daily tablets of 150 mg) vs placebo | no estimate extracted | 1 study · 21 participants | Low Downgraded: imprecision |
Eplerenone (25 mg daily) compared to placebo for DMD
Population: boys with DMD and left ventricular ejection fraction 45% or more
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cardiac function: change (decline) from baseline in left ventricular strain Eplerenone (25 mg daily) vs placebo | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision |
Change in cardiac function: change in LVEF (baseline to 6 months) Eplerenone (25 mg daily) vs placebo | no estimate extracted | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision |
Size of metabolically abnormal areas of myocardium (baseline to 12 months) Eplerenone (25 mg daily) vs placebo | no estimate extracted | 1 study · 42 participants | Low Downgraded: risk of bias, imprecision |
Improvements in quality of life measures Eplerenone (25 mg daily) vs placebo | no estimate extracted | NR | No studies |
Adverse events Eplerenone (25 mg daily) vs placebo | RR 0.37 [0.02, 8.48] | 1 study · 42 participants | Very low Downgraded: risk of bias, imprecision |
Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) versus placebo for DMD and BMD
Population: people with DMD or BMD (ages not stated)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cardiac function: ejection fraction Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Size of metabolically abnormal areas of myocardium Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo | no estimate extracted | NR | No studies |
Improvements in quality of life measures Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo | no estimate extracted | NR | No studies |
Adverse events Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision, indirectness |